Epigenetics is one of the most promising and expanding fields in the current biomedical research landscape. Since the inception of epigenetics in the 1940s, the discoveries regarding its implications in normal and disease biology have not stopped, compiling a vast amount of knowledge in the past decade. The field has moved from just one recognized marker, DNA methylation, to a variety of others, including a wide spectrum of histone modifications. From the methodological standpoint, the successful initial single gene candidate approaches have been complemented by the current comprehensive epigenomic approaches that allow the interrogation of genomes to search for translational applications in an unbiased manner. Most important, the discovery of mutations in the epigenetic machinery and the approval of the first epigenetic drugs for the treatment of subtypes of leukemias and lymphomas has been an eye-opener for many biomedical scientists and clinicians. Herein, we will summarize the progress in the field of cancer epigenetics research that has reached mainstream oncology in the development of new biomarkers of the disease and new pharmacological strategies.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Waddington, C.H. The epigenotype. Endeavour 1, 18–20 (1942).
Berger, S.L., Kouzarides, T., Shiekhattar, R. & Shilatifard, A. An operational definition of epigenetics. Genes Dev. 23, 781–783 (2009).
Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159 (2008).
Jones, P.A. & Baylin, S.B. The epigenomics of cancer. Cell 128, 683–692 (2007).
Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21 (2002).
Wang, Y. & Leung, F.C. An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics 20, 1170–1177 (2004).
Suzuki, M.M. & Bird, A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9, 465–476 (2008).
Futscher, B.W. et al. Role for DNA methylation in the control of cell type specific maspin expression. Nat. Genet. 31, 175–179 (2002).
Hattori, N. et al. Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells. J. Biol. Chem. 279, 17063–17069 (2004).
Doi, A. et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41, 1350–1353 (2009).
Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766–770 (2008).
Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315–322 (2009).
Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129–1133 (2010).
Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).
Allis, C.D. et al. New nomenclature for chromatin-modifying enzymes. Cell 131, 633–636 (2007).
Li, B., Carey, M. & Workman, J.L. The role of chromatin during transcription. Cell 128, 707–719 (2007).
Barski, A. et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823–837 (2007).
Rosenfeld, J.A. et al. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genomics 10, 143 (2009).
Mikkelsen, T.S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553–560 (2007).
Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286–298 (2007).
Feinberg, A.P. Cancer epigenetics is no Mickey Mouse. Cancer Cell 8, 267–268 (2005).
Jones, P.A. & Laird, P.W. Cancer epigenetics comes of age. Nat. Genet. 21, 163–167 (1999).
Irizarry, R.A. et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41, 178–186 (2009).
Eden, A., Gaudet, F., Waghmare, A. & Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455 (2003).
Howard, G., Eiges, R., Gaudet, F., Jaenisch, R. & Eden, A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27, 404–408 (2008).
Rodriguez, J. et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 66, 8462–9468 (2006).
Ogawa, O. et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362, 749–751 (1993).
Watt, P.M., Kumar, R. & Kees, U.R. Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia. Genes Chromosom. Cancer 29, 371–377 (2000).
Wilson, A.S., Power, B.E. & Molloy, P.L. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 1775, 138–162 (2007).
Saito, Y. et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435–443 (2006).
Huang, Y.W. et al. Epigenetic repression of microRNA-129–2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 69, 9038–9046 (2009).
Lujambio, A. et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67, 1424–1429 (2007).
Toyota, M. et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 68, 4123–4132 (2008).
Ley, T.J. et al. DNMT3A Mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2333 (2010).
Burmeister, T. et al. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood 113, 4011–4015 (2009).
Meyer, C. et al. New insights to the MLL recombinome of acute leukemias. Leukemia 23, 1490–1499 (2009).
Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).
Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839–843 (2010).
Fraga, M.F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4is a common hallmark of human cancer. Nat. Genet. 37, 391–400 (2005).
Seligson, D.B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262–1266 (2005).
Chan, E.M. et al. MOZ and MOZ-CBP cooperate with NF-κB to activate transcription from NF-κB–dependent promoters. Exp. Hematol. 35, 1782–1792 (2007).
Yang, X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 32, 959–976 (2004).
Ferrari, R. et al. Epigenetic reprogramming by adenovirus e1a. Science 321, 1086–1088 (2008).
Rasti, M., Grand, R.J., Mymryk, J.S., Gallimore, P.H. & Turnell, A.S. Recruitment of CBP/p300, TATA-binding protein and S8 to distinct regions at the N terminus of adenovirus E1A. J. Virol. 79, 5594–5605 (2005).
Gayther, S.A. et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24, 300–303 (2000).
Gorrini, C. et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448, 1063–1067 (2007).
Bolden, J.E., Peart, M.J. & Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769–784 (2006).
Ropero, S. et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38, 566–569 (2006).
Saunders, L.R. & Verdin, E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26, 5489–5504 (2007).
Pruitt, K. et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2, e40 (2006).
Krivtsov, A.V. & Armstrong, S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823–833 (2007).
Chi, P., Allis, C.D. & Wang, G.G. Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10, 457–469 (2010).
Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 6, 731–740 (2004).
Bracken, A.P. & Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9, 773–784 (2009).
Lu, C. et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185–197 (2010).
Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).
Berdasco, M. et al. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc. Natl. Acad. Sci. USA 106, 21830–21835 (2009).
Wang, G.G., Cai, L., Pasillas, M.P. & Kamps, M.P. NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 9, 804–812 (2007).
Herman, J.G. & Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042–2054 (2003).
Costello, J.F. et al. Aberrant CpG-island methylation has non-random and tumour-type–specific patterns. Nat. Genet. 24, 132–138 (2000).
Esteller, M., Corn, P.G., Baylin, S.B. & Herman, J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225–3229 (2001).
Laird, P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253–266 (2003).
Shivapurkar, N. & Gazdar, A.F. DNA methylation based biomarkers in non-invasive cancer screening. Curr. Mol. Med. 10, 123–132 (2010).
Esteller, M. et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67–70 (1999).
Chen, W.D. et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 97, 1124–1132 (2005).
Hoque, M.O. et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl. Cancer Inst. 98, 996–1004 (2006).
Belinsky, S.A. et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 66, 3338–3344 (2006).
Bailey, V.J. et al. MS-qFRET: a quantum dot-based method for analysis of DNA methylation. Genome Res. 19, 1455–1461 (2009).
Li, M. et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 27, 858–863 (2009).
Belinsky, S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 4, 707–717 (2004).
Lee, W.H. et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91, 11733–11737 (1994).
Esteller, M. et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 58, 4515–4518 (1998).
Brooks, J.D. et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev. 7, 531–536 (1998).
Jerónimo, C. et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst. 93, 1747–1752 (2001).
Cairns, P. et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7, 2727–2730 (2001).
Hoque, M.O. et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. 23, 6569–6575 (2005).
Bastian, P.J. et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 179, 529–534 (2008).
Richiardi, L. et al. Promoter methylation in APC, RUNX3 and GSTP1 and mortality in prostate cancer patients. J. Clin. Oncol. 27, 3161–3168 (2009).
Weigelt, B., Baehner, F.L. & Reis-Filho, J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263–280 (2010).
Hernandez-Vargas, H. et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS ONE 5, e9749 (2010).
Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).
Brock, M.V. et al. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 358, 1118–1128 (2008).
Lujambio, A. et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA 105, 13556–13561 (2008).
Fernandez, A.F. et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 19, 438–451 (2009).
Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350–1354 (2000).
Hegi, M.E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
Paz, M.F. et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 10, 4933–4938 (2004).
Esteller, M., Hamilton, S.R., Burger, P.C., Baylin, S.B. & Herman, J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793–797 (1999).
Weller, M. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6, 39–51 (2010).
Martinez, R. et al. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J. Neurooncol. 83, 91–93 (2007).
Stupp, R. et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712–2718 (2010).
Chakravarti, A. et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin. Cancer Res. 12, 4738–4746 (2006).
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
McCormack, A.I. et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin. Endocrinol. 71, 226–233 (2009).
Esteller, M. et al. Hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94, 26–32 (2002).
Watson, A.J. et al. Tumor O6-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin. Cancer Res. 16, 743–749 (2010).
Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. & Brown, R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60, 6039–6044 (2000).
Agrelo, R. et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl. Acad. Sci. USA 103, 8822–8827 (2006).
Ibanez de Caceres, I. et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29, 1681–1690 (2010).
Veeck, J.R.S., Setien, F., Gonzalez-Suarez, E., Osorio, A., Benitez, J., Herman, J.G. & Esteller, M. BRCA1 CpG island hypermethylation predicts sensitivity to poly (adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 28, e563–e564 (2010).
Koga, Y. et al. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J. Gastroenterol. 41, 133–139 (2006).
Toyota, M. et al. Epigenetic inactivation of CHFR in human tumors. Proc. Natl. Acad. Sci. USA 100, 7818–7823 (2003).
Ferreri, A.J. et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br. J. Haematol. 126, 657–664 (2004).
Dejeux, E. et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol. Cancer 9, 68 (2010).
Billam, M., Witt, A.E. & Davidson, N.E. The silent estrogen receptor: Can we make it speak? Cancer Biol. Ther. 8, 485–496 (2009).
Laird, P.W. Principles and challenges of genome-wide DNA methylation analysis. Nat. Rev. Genet. 11, 191–203 (2010).
Li, M. et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med. Genomics 2, 34 (2009).
Balch, C. et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther. 4, 1505–1514 (2005).
Byrd, J.C. et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105, 959–967 (2005).
Garcia, J.S., Jain, N. & Godley, L.A. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco. Targets Ther. 3, 1–13 (2010).
O'Connor, O.A. et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24, 166–173 (2006).
Piekarz, R.L. et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27, 5410–5417 (2009).
Beumer, J.H. et al. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother. Pharmacol. 62, 363–368 (2008).
Flotho, C. et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23, 1019–1028 (2009).
Fang, M.Z. et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63, 7563–7570 (2003).
Lee, B.H., Yegnasubramanian, S., Lin, X. & Nelson, W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 280, 40749–40756 (2005).
Segura-Pacheco, B. et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 9, 1596–1603 (2003).
Villar-Garea, A., Fraga, M.F., Espada, J. & Esteller, M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 63, 4984–4989 (2003).
Siedlecki, P. et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J. Med. Chem. 49, 678–683 (2006).
Keppler, B.R. & Archer, T.K. Chromatin-modifying enzymes as therapeutic targets–Part 1. Expert Opin. Ther. Targets 12, 1301–1312 (2008).
Joseph, J. et al. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23, 6304–6315 (2004).
Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11, 77–84 (2005).
Bedalov, A., Gatbonton, T., Irvine, W.P., Gottschling, D.E. & Simon, J.A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA 98, 15113–15118 (2001).
Bitterman, K.J., Anderson, R.M., Cohen, H.Y., Latorre-Esteves, M. & Sinclair, D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277, 45099–45107 (2002).
Grozinger, C.M., Chao, E.D., Blackwell, H.E., Moazed, D. & Schreiber, S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276, 38837–38843 (2001).
Ota, H. et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25, 176–185 (2006).
Kojima, K. et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 373, 423–428 (2008).
Heltweg, B. et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66, 4368–4377 (2006).
Lara, E. et al. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28, 781–791 (2009).
Lain, S. et al. Discovery, in vivo activity and mechanism of action of a small-molecule p53 activator. Cancer Cell 13, 454–463 (2008).
Balasubramanyam, K. et al. Curcumin, a novel p300/CREB-binding protein–specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase–dependent chromatin transcription. J. Biol. Chem. 279, 51163–51171 (2004).
Mukhopadhyay, A. et al. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21, 8852–8861 (2002).
Shishodia, S., Amin, H.M., Lai, R. & Aggarwal, B.B. Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 70, 700–713 (2005).
Shishodia, S., Chaturvedi, M.M. & Aggarwal, B.B. Role of curcumin in cancer therapy. Curr. Probl. Cancer 31, 243–305 (2007).
Balasubramanyam, K. et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 279, 33716–33726 (2004).
Sun, Y., Jiang, X., Chen, S. & Price, B.D. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett. 580, 4353–4356 (2006).
Stimson, L. et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther. 4, 1521–1532 (2005).
Greiner, D., Bonaldi, T., Eskeland, R., Roemer, E. & Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3–9. Nat. Chem. Biol. 1, 143–145 (2005).
Isham, C.R. et al. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 109, 2579–2588 (2007).
Tan, J. et al. Pharmacologic disruption of polycomb-repressive complex 2–mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050–1063 (2007).
Cheng, D. et al. Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem. 279, 23892–23899 (2004).
El Messaoudi, S. et al. Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the cyclin E1 gene. Proc. Natl. Acad. Sci. USA 103, 13351–13356 (2006).
Mai, A. et al. epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase and class III deacetylase (sirtuin) inhibitors. J. Med. Chem. 51, 2279–2290 (2008).
Lee, M.G., Wynder, C., Schmidt, D.M., McCafferty, D.G. & Shiekhattar, R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13, 563–567 (2006).
Dawson, M.A. et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature 461, 819–822 (2009).
Dar, A.A., Goff, L.W., Majid, S., Berlin, J. & El-Rifai, W. Aurora kinase inhibitors—rising stars in cancer therapeutics? Mol. Cancer Ther. 9, 268–278 (2010).
Hirota, T., Lipp, J.J., Toh, B.H. & Peters, J.M. Histone H3 serine 10 phosphorylation by aurora B causes HP1 dissociation from heterochromatin. Nature 438, 1176–1180 (2005).
den Hollander, J. et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116, 1498–1505 (2010).
Görgün, G. et al. A novel aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115, 5202–5213 (2010).
Steeghs, N. et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 27, 5094–5101 (2009).
Yu, C. et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin. Cancer Res. 13, 1140–1148 (2007).
Zhang, B. et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427–442 (2010).
Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
Kantarjian, H.M. et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116, 3163–3170 (2010).
Kanzaki, M. et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol. Rep. 17, 761–767 (2007).
Yang, X., Lay, F., Han, H. & Jones, P.A. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 31, 536–546 (2010).
Ma, X., Ezzeldin, H.H. & Diasio, R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69, 1911–1934 (2009).
Geng, L. et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 66, 11298–11304 (2006).
Beltran, A. et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26, 2791–2798 (2007).
Marchion, D.C., Bicaku, E., Daud, A.I., Sullivan, D.M. & Munster, P.N. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol. Cancer Ther. 4, 1993–2000 (2005).
Brueckner, B. et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol. Cancer Ther. 9, 1256–1264 (2010).
Li, Y. et al. The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol. 8, e1000533 (2010).
Gilbert, J. et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7, 2292–2300 (2001).
Göttlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969–6978 (2001).
Terao, Y. et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int. J. Cancer 94, 257–267 (2001).
Chen, S., Ye, J., Kijima, I. & Evans, D. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc. Natl. Acad. Sci. USA 107, 11032–11037 (2010).
Khan, N. et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409, 581–589 (2008).
Qian, X. et al. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int. J. Cancer 122, 1400–1410 (2008).
Steele, N.L. et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14, 804–810 (2008).
Itoh, Y., Suzuki, T. & Miyata, N. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des. 14, 529–544 (2008).
Fournel, M. et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 7, 759–768 (2008).
Hess-Stumpp, H., Bracker, T.U., Henderson, D. & Politz, O. MS-275, a potent orally available inhibitor of histone deacetylases—the development of an anticancer agent. Int. J. Biochem. Cell Biol. 39, 1388–1405 (2007).
Lucas, D.M. et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18, 1207–1214 (2004).
The authors declare no competing financial interests.
About this article
Cite this article
Rodríguez-Paredes, M., Esteller, M. Cancer epigenetics reaches mainstream oncology. Nat Med 17, 330–339 (2011). https://doi.org/10.1038/nm.2305
KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling
Nature Communications (2022)
International Journal of Clinical Oncology (2022)
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer
Genome Medicine (2021)
Gene-associated methylation status of ST14 as a predictor of survival and hormone receptor positivity in breast Cancer
BMC Cancer (2021)
Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification
BMC Cancer (2021)